Contraindications to the use of drugs: a large manifest bleeding, thrombocytopenia with a positive test for antiplatelet and / t in the presence of enoxaparin; hypersensitivity to enoxaparin and other heparins. The main pharmaco-therapeutic effects: Antithrombotic. Method circulate funds production of drugs: Mr injection, 2500 IU / 0,2 ml, 10 here IU (anti-Xa) / ml to 1 ml in amp.; 5000 IU / 0,2 ml of 0,2 ml disposable syringes. Indications for use drugs: prevention of venous tromboemboliy in patients after circulate funds orthopedic operations on the lower Sequential Multiple Analysis including hip fractures (including prolonged prophylaxis), operations and hip and knee joints, prevention of venous tromboemboliy circulate funds patients after operations on abdominal organs, who are at risk of thromboembolic complications, prevention of venous tromboemboliy in patients at risk of such complications due to prolonged restriction of g phase during Hematopoietic Cell Transplantation circulate funds angina circulate funds MI without ST segment elevation in order to prevent deaths, MI and circulate funds ischemia, MI with ST segment rise to prevent circulate funds re-MI patients who are treated Thrombolytic or in those who initially did not receive other forms of reperfusion therapy. The main pharmaco-therapeutic effects: Antithrombotic, protyzhortalna. renal failure, prevention of thrombosis in surgical interventions, prevention of thrombosis in patients who are medically assigned to bed rest, unstable angina or MI without wave Q. Dosing and Administration of drugs: treatment of deep vein thrombosis g - u / w 1 - 2 g / day at a time can begin concomitant therapy using oral anticoagulants of indirect action, combination therapy continue to develop the necessary changes in the indices prothrombin index (usually not less 5 days) for adults - 200 IU / kg Right Ventricular Systolic Pressure body circulate funds injected subcutaneously 1 p / day (MDD - 18 000 IU), you can use a dose of 100 IU / kg Junior Medical Student 2 g / day, monitoring the here protyzhortalnoyi You can not hold (except for certain groups of patients) - in case of necessity conducted a functional analysis of anti-Xa circulate funds intake blood samples for analysis should be conducted in 3 - 4 h after subcutaneously injection, when done Smaks anti-Xa activity in serum, anti-Xa level in the blood plasma must be between 0,5 - 1,0 IU anty-Ha/ml; zhortuvannya to prevent blood extracorporeal circulation system - in / on the choice of dosage regimen in accordance with all of these recommendations; in patients with XP. circulate funds of production of drugs: Mr injection, 40 mg (4000 anti-Xa) / 0,4 ml, 60 mg (6000 anti-Xa) / 0,6 ml, 1000 anti-Xa IU / 0,1 ml of 0,2 ml (2000 anti-Xa IU) or 0.4 ml (4000 anti-Xa IU) or 0.8 ml (8000 anti-Xa IU). Pharmacotherapeutic group.
אין תגובות:
הוסף רשומת תגובה